Dexcom Inc 's Revenue in the fiscal year 2025 $ 4,661.90 millions
Dexcom Inc 's Revenue in the fiscal year 2024 $ 4,032.20 millions
Dexcom Inc 's Revenue in the fiscal year 2023 $ 3,621.90 millions
Dexcom Inc 's Revenue in the fiscal year 2022 $ 2,909.80 millions
Dexcom Inc 's Revenue in the fiscal year 2021 $ 2,448.50 millions
DXCM Revenue second quarter 2026 Y/Y Growth Comment
Dexcom Inc reported Revenue increase of 13.11% year on year in the second quarter 2026, to $ 1,308.40 millions, this is lower than Dexcom Inc 's recent average Revenue improvement of 35.72%.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 120 other companies have achieved higher Revenue growth. While Dexcom Inc ' s Revenue growth of 13.11% ranks overall at the positon no. 2225 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Dexcom Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
51.1 %
8.93 %
-17.01 %
(Jun 30 2011)
DXCM's II. Quarter Q/Q Revenue Comment
Dexcom Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.83%, to $ 1,308.40 millions, from $1,191.30 millions in the first quarter.
Within Medical Equipment & Supplies industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Dexcom Inc 's Revenue growth quarter on quarter, overall rank is 832.
Dexcom Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.83%, to $ 1,308.40 millions, from $1,191.30 millions in the first quarter.
Within Medical Equipment & Supplies industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Dexcom Inc 's Revenue growth quarter on quarter, overall rank is 832.
Dexcom Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 4,968.80
$ 4,817.20
$ 4,661.90
$ 4,515.00
$ 4,300.40
Y / Y Revenue Growth (TTM)
15.54 %
16.15 %
15.62 %
14.21 %
9.32 %
Year on Year Revenue Growth Overall
Ranking
# 1588
# 326
# 1092
# 742
# 63
Seqeuential Revenue Change (TTM)
3.15 %
3.33 %
3.25 %
4.99 %
3.69 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2225
# 2180
# 2030
# 2030
# 563
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Dexcom Inc 's cumulative twelve months Revenue were $ 4,969 millions, company would post below average annual Revenue growth of 3.69% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Dexcom Inc 's Revenue growth from the 1191.3% growth in Mar 31 2026.
In the Healthcare sector 257 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 326 to 1588.
With the quarterly Revenue reported in the Jun 30 2026 period, Dexcom Inc 's cumulative twelve months Revenue were $ 4,969 millions, company would post below average annual Revenue growth of 9.1% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Dexcom Inc 's Revenue growth from the 1191.3% growth in Mar 31 2026.
In the Healthcare sector 257 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 326 to 1588.
About Dexcom Inc Revenue Growth Rates (DXCM), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
22.48%